Login / Signup

Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study.

Manuela di FuscoXiaowu SunKristen E AllenAlon YehoshuaAlexandra BerkMary B AlvarezThomas M PorterJinma RenLaura PuzniakSantiago M C LopezJoseph Christopher Cappelleri
Published in: Vaccines (2024)
Compared with unvaccinated participants, participants vaccinated with the bivalent were associated with approximately 40% lower risk of long COVID and less symptom burden over the six-month study duration.
Keyphrases
  • coronavirus disease
  • sars cov
  • randomized controlled trial
  • systematic review
  • respiratory syndrome coronavirus
  • risk factors